BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Abortion Pill Deaths Probed


12/1/2005 11:22:17 AM

The recent deaths of five young women from an otherwise rare infection within a week of taking the abortion pill Mifeprex -- also known as RU 486 -- are pitting those who say the drug is a danger to women against those who believe it is a largely safe method of terminating pregnancy. Reporting in the Dec. 1 issue of the New England Journal of Medicine, experts at the U.S. Centers for Disease Control and Prevention outlined four U.S. cases (the fifth case involved a Canadian woman) where otherwise healthy young women contracted a Clostridium sordellii bacterial infection. In each case, the women became very ill within days of their medical abortion and died of toxic shock syndrome related to the infection. The families of three of those four women are suing the drug's maker, Danco Laboratories. And last week, the The New York Times quoted anonymous sources at the U.S. Food and Drug Administration as saying the agency would convene a special scientific meeting on the deaths early next year, in cooperation with the CDC. Complicating matters is the fact that experts have yet to find a causative link between the use of Mifeprex (mifepristone) -- the so-called "abortion pill" that is usually taken with a second drug, misoprostol -- and C. sordellii infection. "That's what's bugging everybody -- there's no obvious pathophysiological link between these medications and this, or any other, infection," said Dr. Michael F. Greene, a professor of obstetrics, gynecology and reproductive biology at Harvard Medical School and director of obstetrics at Massachusetts General Hospital in Boston. Greene is also the author of a journal editorial commenting on the CDC report. In the fall of 2000, FDA officials first approved the use of Mifeprex for use in the early (less than seven weeks gestation) termination of pregnancy, after 54 months of deliberation and review. The original approval included a "black-box" warning advising prescribers of a potential risk for incomplete abortion and complications such as ectopic pregnancy and septic shock, associated with the drug's use. According to Danco, Mifeprex has been used in more than 500,000 abortions since it first gained U.S. approval five years ago.

Read at HealthDay

HealthDay
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES